Long-term course and outcome of functional capacity in rheumatoid arthritis: The effect of disease activity and radiologic damage over time
1999/09/01 by K. W. Drossaers-Bakker, K.W. Drossaers-Bakker, M. De Buck +9 · 27 citations
Medicine · #Rheumatoid Arthritis Research and Therapies #Osteoarthritis Treatment and Mechanisms #Spondyloarthritis Studies and Treatments
paper · doi:10.1002/1529-0131(199909)42:9<1854::aid-anr9>3.0.co;2-f
Abstract
OBJECTIVE: To investigate the evolution of functional capacity, disease activity, and joint destruction over time in a 12-year prospective cohort of rheumatoid arthritis (RA) patients, and to study the relative contribution of disease activity and joint destruction to the loss of functional capacity. METHODS: One hundred thirty-two female patients with recent-onset RA were assessed at 0, 3, 6, and 12 years of followup for functional capacity (Health Assessment Questionnaire [HAQ] score), disease activity (Disease Activity Score [DAS]), and joint destruction (Sharp score of radiologic damage). RESULTS: The Sharp score deteriorated steadily over time, while the HAQ score and DAS showed a variable course. The DAS correlated strongly with the HAQ score throughout the disease course. The correlation between the Sharp score and the HAQ score was weak at study start, but became strong after 12 years. After 12 years of followup, disease activity was the main determinant of the HAQ score when entered in a multivariate analysis. CONCLUSION: Functional capacity is strongly influenced by disease activity throughout the course of RA. Even in longstanding RA, disease activity proves to be the main determinant of the HAQ score for functional capacity.
Citations
Cited by
- Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity
- Association of early radiographic damage with impaired physical function in rheumatoid arthritis: A ten‐year, longitudinal observational study in 238 patients
- Percentile benchmarks in patients with rheumatoid arthritis: Health Assessment Questionnaire as a quality indicator (QI). [europepmc]
- Imbalance of local bone metabolism in inflammatory arthritis and its reversal upon tumor necrosis factor blockade: direct analysis of bone turnover in murine arthritis. [europepmc]
- The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? [europepmc]
- Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. [europepmc]
- Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. [europepmc]
- Developments in the clinical understanding of rheumatoid arthritis. [europepmc]
- Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial. [europepmc]
- Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. [europepmc]
- Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. [europepmc]
- Predictors of depression in a multiethnic cohort of patients with rheumatoid arthritis. [europepmc]
- Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. [europepmc]
- CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis. [europepmc]
- Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. [europepmc]
- Sleep duration and reported functional capacity among black and white US adults. [europepmc]
- Indicators of walking speed in rheumatoid arthritis: relative influence of articular, psychosocial, and body composition characteristics. [europepmc]
- Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. [europepmc]
- Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid Arthritis. [europepmc]
- Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. [europepmc]
- Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. [europepmc]
- Changes in peripheral blood lymphocyte subsets during arthritis development in arthralgia patients. [europepmc]
- Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis. [europepmc]
- Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). [europepmc]
- Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. [europepmc]
- Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. [europepmc]
- The extra-articular impacts of rheumatoid arthritis: moving towards holistic care. [europepmc]
Related